Rise Therapeutics plans to launch a Phase 1 clinical trial testing R-2487, its experimental oral therapy for autoimmune diseases, in people with Sjögren’s disease. R-2487, which leverages bacterial proteins to suppress the abnormal immune responses in autoimmune diseases like Sjögren’s, “is disease-modifying, focusing on long-term immune correction rather than short-term symptom relief,” Christian Furlan Freguia, […] The post Rise’s R-2487 moves toward clinical testing as Sjögr...
